Fc-optimized anti-CD25 for tumour specific cell depletion

• 收藏
• 分享

专利权人:

Tusk Therapeutics Ltd;Cancer Research Technology Limited

发明人:

Goubier, Anne,Merchiers, Pascal,Salimu, Josephine,Goyenechea Corzo, Beatriz,Moulder, Kevin,Quezada, Sergio,Peggs, Karl,Arce Vargas, Frederick,Solomon, Isabelle

申请号：

AU2018233976

公开号：

AU2018233976A1

申请日:

2018.03.13

申请国别(地区):

AU

年份:

2019

代理人:

摘要：

The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2 - CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/